Study of dose-dependent effect of 2-ethyl-6-methyl-3 hydroxypyridine succinate on the contractile function of  isolated rat heat by Kesarev, O. G. et al.
 Study of dose-dependent effect of 2-ethyl-6-methyl-3 hydroxypyridine succinate on the contractile function of 
isolated rat heat / O.G. Kesarev, L.M. Danilenko, M.V. Pokrovskii, A.S. Timokhina, A.V. Khovanskii // Research 
result: pharmacology and clinical pharmacology. – 2017. – Vol. 3, №1. – P. 3-9. 
3 
 
RESEARCH RESULT:  
























STUDY OF DOSE-DEPENDENT EFFECT OF 2-ETHYL-6-METHYL-3 
HYDROXYPYRIDINE SUCCINATE ON THE CONTRACTILE FUNCTION 
OF ISOLATED RAT HEART 
 
1
"Russian scientific center for security biologically active substances" (JSC "all-Russian scientific centre BAS")  
Moscow region, Noginsk district, Staraya Kupavna, Kirov str., 23, 142450, Russia.  
2
Belgorod State University, 85 Pobedy St., Belgorod, 308015, Russia  E-mail: Danilenko_L@bsu.edu.ru 
 
Abstract 
In experiments on the isolated rat heart there were studied the effects of different doses  
(21.43 mg/kg/day and 85.72 mg/kg/day) 2-ethyl-6-methyl-3 hydroxypyridine succinate 
("EkoPharmInvest", Russia), on the contractile function of isolated hearts subjected to prior 
doxorubicin model (20 mg/kg, intraperitoneal) of pathology. The dynamic of the power mechanisms 
of ion transport was evaluated by imposing high heart rate (480 BPM) and increase concentration of 
Са2+ to 5 mmol in perfusate. The results indicate that Mexicor at the dose of 21.43 mg/kg/day does not 
provide a cardioprotective effect in this model of pathology. Mexicor has the cardioprotective effect at 
the dose of 85.72 mg/kg/day in relation to the isolated heart, that is resulted in the recovery of the 
contractile function of the heart and reducing the "diastole defect" (SТТI). 




One of the mechanisms of pathogenesis and 
progression of ischaemic alterations of the 
myocardium is oxidative stress in the myocardium, 
leading to damage of cardiomyocytes  and related 
violations of the functional properties of the cardiac 
muscle [1-7]. The result of these complex changes is 
the left ventricular (LV) remodeling with subsequent 
progression to systolic and diastolic dysfunction, the 
development of reinfarctions, embolic stroke, sudden 
death [8-10]. 
In the present cardiology practice, along with 
antianginal, hypolipidemic, anticoagulant and 
antiplatelet drugs, patients with CHF and acute 
coronary syndrome are prescribed cardioprotective 
medications. The antioxidants are of particular 
interest as one of the promising groups of 
cardioprotective drugs, allowing to save viable 
myocardium, to limit damage and accelerate recovery 
of contractile activity of the myocardium [11-19]. 
Main part 
The research objective of this study was to study 
the effect of 2-ethyl-6-methyl-3 hydroxypyridine 
succinate in different doses on the contractile 
function of isolated heart in model of doxorubicin-
induced cardiomyopathy. 
Materials and methods. The study was 
performed in isolated hearts of Wistar rats weighing 
300±20 g. The experiment was performed with the 
requirements and principles of humane treatment of 
experimental animals. All rats were divided into 4 
experimental groups of 8 animals. The first group, 
the control was injected intraperitoneally with 
physiological solution. The second group was 
injected intraperitoneally with doxorubicin (Teva) at 
a cumulative dose of 20 mg/kg once. The third was 
administrated doxorubicin and Mexicor (ZAO 
"MiraxBioPharma") at the dose of 21.43 mg/kg/day. 
The fourth group was administrated doxorubicin and 
Mexicor at the dose of 85.72 mg/kg/day. The dose of 
Mexicor was calculated taking into account the 
coefficient of interspecies transfer of human doses on 
the rat. Mexicor was administrated daily 1 time per 
day. Animals were taken out from experiment after 
48 hours. Heart recovery from animals had been 
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performed under anesthesia by Zoletil (30 mg/kg), 
than hearts were placed in ice (2-4°C) solution of 
Krebs Henseleit the following composition (mmol): 
NaCl – 118.5; KCl – 4.7; MgSO4/7Н2О – 1.2; 
KH2PO4 – 1.2; CaCl2 – 1.5; glucose – 11.1;  
NaHCO3 – 25.0. The pH of the solution during the 
whole experiment was 7.4. After asystolism aorta 
was isolated and connective tissue was separated. 
Then the aorta was cannulated and there was 
performed a retrograde perfusion of the heart using 
Langendorff method in the mode of flow perfusion 
for 20 min with a solution of Krebs-Henseleit, 
saturated with Carbogen (95 % O2 + 5% CO2) at 
37°C and at a pressure of 100 mm Hg and perfusate 
speed of 10 ml/min. Contractile function of the heart 
was recorded using inserted into the cavity of the left 
ventricle a latex balloon connected to a pressure 
sensor in assessment equipment МР150 
("BiopacSystems, Inc" (California, USA)). The 
balloon was filled with distilled water, the volume of 
which was sufficient to keep left ventricular end 
diastolic pressure at the level of 3-5 mm Hg. Using 
the original software program AcqKnowledge 
("BiopacSystems, Inc" (California, USA)), all rats 
there were recorded indices of contractility: left 
ventricule pressure (LVP, mm Hg), heart rate (HR, 
BPM), maximum rate of myocardial contraction 
(+dP/dtmax, mm Hg/sec), the maximum rate of 
myocardial relaxation (-dP/dtmax, mm Hg/sec). Then 
to determine the dynamics of diastolic tension of the 
heart there was used the method of HR increasing to 
480 BPM in concentration of Ca
2+
 of 5 mmol/l. To 
create a high HR (480 BPM) the metallic cannula 
there was attached a ground connector of electrical 
stimulator, and left atrial appendage was attached a 
positive connector. After 20 minutes of perfusion 
with a solution with a high concentration of Ca
2+
  
(5 mmol/l), the heart was subjected to electrical 
stimulation pulses for 15 seconds using the 
equipment STM 200-1 ("BiopacSystems, Inc" 
(California, USA)). 
To assess the spare capacity of the myocardium 
there was used Тension-Тime Index (TTI), it is the 
index of the change in mechanical stress of the 
myocardium, calculated by the dynamic curve of 
intraventricular pressure by the planimetration 
method (i.e. measurement the area under the curve). 
The area under the curve was calculated by adding 
areas of trapezoids, which is equal to the product of 
its height on the middle line. The index of diastolic 
dysfunction or "diastole defect" (SТТI) was expressed 
in conditional unit (cu). About the intensity of 
cardioprotective effect of Mexicor at the doses of 
21.43 mg/kg/day and 85.72 mg/kg/day we went by 
the influence of the drug on the SТТI. 
A statistical significance of the changes of the 
absolute measures were determined by a difference 
method of variation statistics, calculating the average 
workshift values, the arithmetical mean probability of 
a possible error (p) by Student tables. The differences 
between the results were considered statistically 
significant when p< 0.05. 
Results and evaluation 
Indices of contractile function of the hearts of all 
experimental groups at the initial state and with 
increasing the concentration of Ca2
+
 to 5 mmol/l are 
presented in table 1 and table 2. 
Studies have shown that in condition of this 
disease changes of contractility are characterized by a 
negative inotropic effect (table 1). 
Table 1 
Indices of contractile function of the rat hearts (M±m; n=8) 
The concentration of Ca2
+







 mm Hg/sec 
-dP/dt, 
 mm Hg/sec 
HR,  
BPM 
Intact animals 87.3±9,2** 1423±162.2** -1265.2±173.2** 248±32.1 
Control 
doxorubicin 48 hours 
before (20 mg/kg) 
64.5±11.2* 1025.7±154.3* -1031.1±159.4* 247±29.4 
Doxorubicin +Mexicor 
21.4 mg/kg/day 
71. 4±6.3* 1117±179.6* -1108±89.3* 221±34.9 
Doxorubicin +Mexicor 
85.72 mg/kg/day 
86.3±10.4** 1276±189.4** -1259.2±149.3** 228±22.9 
 
Comment: * – р<0.05 in comparison with intact animals; ** – р<0.05 in comparison with control group. 
 
 
Changes in most hemodynamic parameters are 
cardiodepressant. When the concentration of Ca
2+
 2.5 
mmol/l, the contractile function of the myocardium is 
most affected, that evidenced by the decrease in 
systolic pressure by 26% in comparison with group 
of intact hearts, and the maximum rates of 
contraction and relaxation (table 1) reduced by 28% 
and 19%, respectively. HR changed little. 
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A further stage of our experiments was to run up 
the concentration of Ca
2+
 to 5 mmol/l in the perfusion 
solution. After 20 minutes of perfusion with a 
solution with a high concentration of Ca
2+
  
(5 mmol/l), the heart was subjected to stimulation by 
electrical impulses for 15 seconds. Perfusion of intact 
hearts and the hearts of the control group by the 
solution with a high concentration of calcium ions 
within the 1 min was shown positive inotropic effect, 
that was reflected in the increase in systolic blood 
pressure and its rate characteristics. Thus, end 
diastolic pressure increased to 20-25 mm Hg and 
formed the " diastole defect"(figure 1a). 
Table 2 
Indices of contractile function of the rat hearts (M±m; n=8) 
The concentration of Ca2
+












Intact animals 127±12.7** 987.4±92.9** -1012.6±113.4** 240±24.1 
Control 
doxorubicin 48 hours 
before (20 mg/kg) 
155±21.2* 533.4±154.3* -561.6±119.2* 273±30.44* 
Doxorubicin +Mexicor 
21.4 mg/kg/day 
135±19.9* 689.5±108.2* -611.9±151.4* 243±27.9* 
Doxorubicin +Mexicor 
85.72 mg/kg/day 
140±15.9** 821±132.4** -778.6±163.9** 254±20.5** 
 
Comment: * – р<0.05 in comparison with intact animals; ** – р<0.05 in comparison with control group. 
 
SТТI coefficient for intact group was 1.4±0.1.cu 
(figure 3). 
In the control group with doxorubicin-induced 
cardiomyopathy in the cardiac stimulation with 
submaximal rate (480 BPM) during the first minute 
of perfusion of the solution with a high concentration 
of calcium ions there was detected positive inotropic 
effect (table 2). Then inotropic effect was neutralized, 
there was observed a pronounced negative inotropic 
effect and increase in contracture heart contraction, 
that leaded to decrease in the power and rate 
characteristics of contractility decreased, there was an 
increase in end diastolic pressure of 40-60 mm Hg 
(figure 1b), and the "diastole defect" SТТI was 8.3±0.3 
cu, that indicates a significant damage and failure of 
calcium pump of cardiomyocytes (figure 3). 
The perfusion of the solution with a high 
concentration of calcium ions leaded to loss of the 
heart contraction rate by 46 % and relaxation rate 
more than 45% in control group (table 2). The data 
indicate that the perfusion of the solution with a high 
concentration of calcium ions and base solution of 
calcium affect the activity of isolated animal hearts 
varying degrees.
 
                         a                                                                b                           
Figure 1. The pressure dynamic in the left ventricle: the hearts of the intact group (a) with doxorubicin 20 mg/kg (b) 
in the cardiac stimulation with submaximal rate (480 BPM). The concentration of Ca
2+
 is 5 mmol/l. 
 
The absence of a pronounced positive inotropic 
effect in the control group and the group injected 
with Mexicor at the dose of 21.4 mg/kg/day, suggest 
the combination dysfunction each of the heart 
contraction processes and the mechanisms 
responsible for the relaxation, the net effect of which 
is the failure of the calcium pumps of myolemma and 
a sarcoplasmic reticulum (table 2). 
In the experimental groups injected with 
Mexicor, we see a cardioprotective effect of it at the 
dose of 85.72 mg/kg/day (table 2). 
 Study of dose-dependent effect of 2-ethyl-6-methyl-3 hydroxypyridine succinate on the contractile function of 
isolated rat heat / O.G. Kesarev, L.M. Danilenko, M.V. Pokrovskii, A.S. Timokhina, A.V. Khovanskii // Research 
result: pharmacology and clinical pharmacology. – 2017. – Vol. 3, №1. – P. 3-9. 
6 
 
RESEARCH RESULT:  
PHARMACOLOGY AND CLINICAL PHARMACOLOGY 
 
 
                                    a                                                                   b                     
Figure 2. The influence of Mexicor the reaction of the heart, caused by the cardiac stimulation  
with submaximal rate (480 BPM). The concentration of Ca2
+
 is 5 mmol.  
a – Mexicor at the dose of 21.43 mg/kg/day; b – Mexicor at the dose of 85.72 mg/kg/day 
 
Mexicor therapy at the dose of 85.7 mg/kg/day 
resulted in a significant reduction of the "diastole 
defect" to 5.3±0.3, that goes to prove a marked 
cardioprotective effect of the drug at this dose  
(figure 2b). 
 
Figure 3. The influence of Mexicor (21.43 mg/kg/day, 85.7 mg/kg/day) on the SТТI, cu  
(under doxorubicin-induced cardiomyopathy). 
Comment: * – р<0.05 in comparison with intact animals; ** – р<0.05 in comparison with control group. 
 
It should be noted that SТТI in the group injected 
with Mexicor at the dose of 21.43 mg/kg/day did not 
decrease significantly and amounted to 7.4±0.1 
(figure 2a). 
Thus, the comparative dynamic analysis of the 
indices of contractile function of the hearts of the 
experimental groups has allowed to establish that 
Mexicor at the dose of 85.7 mg/kg/day contributed 
the maximum increase of stability of the contractile 
apparatus of cardiac muscle, that proves 
demonstratively a pronounced cardioprotective effect 
of it. 
A comparative analysis of the cardioprotective 
effect of this drug has revealed that low dose of 
Mexicor (21.43 mg/kg/day) does not have 
cardioprotective effect in this model of pathology. 
Free radical formation on the background of 
reducing the amount of antioxidants leads to increase 
of oxidative stress, that can be the direct cause of 
cardiomyopathy and heart failure in doxorubicin-
induced cardiomyopathy [20, 21, 22]. 
It is known that different reactive oxygen 
species (O
2-
, H2O2, OH) have different capacities to 
initiate the subsequent free radical reactions. A 
superoxide anion (O
2-
) has the lowest activity, and a 
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hydroxyl radical (OH) has the maximum activity. OH 
is formed in the Haber-Weiss reaction, with the 
participation of superoxide dismutase and ions of 
ferrous iron (Fe
2+
 ions). One of the alleged reasons of 
doxorubicin-induced cardiomyopathy is associated 
with effect on iron metabolism: anthracyclines blind 
with Fe
2+
 ions, that leads to the formation of hydroxyl 
radical and promotes the release of Fe
2+
 from ferritin, 
further exacerbating oxidative stress [23-27]. 
So if in the cytoplasm of cells there are conditions 
for the chelation or oxidation of ferrous iron to the 
catalytically inactive ferric iron (Fe
3+
 ions) and thereby 
decreasing the effective concentration of hydroxyl 
radicals, it will create the conditions to achieve micro 
molar concentrations of reactive oxygen species in the 
cytoplasm of cells. Mexicor has a antioxidative activity 
and plays an important role in the regulation of free 
radical mechanisms [28, 29, 30]. As an example it can 
be suggested that mexicor at the dose of 85.7 mg/kg/day 





[31]. In addition, monitoring the 
concentration of Fe
2+
 may have a role in the regulation 
of free radical reactions: lipid peroxidation, inactivation 
of proteins and nucleic acids. It is well known that the 
activation of free radical reactions is observed in the 
initiation and development of a number of 
inflammatory diseases. This circumstance allowed to 
call this disease "free radical pathologies". Activation of 
the free radical reactions in development of free radical 
pathologies is due to two main reasons: the increase in 
the production of primary and secondary radical 
initiators and participants of the free radical reactions 
(the stage of initiation of the free radical reactions) and 
the appearance of the catalysts of the free radical 
reactions, of Fe
2+
 ions in the main (stage oxidation chain 
branching) [32, 33]. It follows that inhibition of free 
radical reactions can be performed by capturing free 





[34, 35, 36]. The latter is particularly important in 
pathologies which are characterized by violation of the 
integrity of blood vessels: stroke, gastric hemorrhage, 
wounds, etc., [21]. Mexicor, possessing the property of 





inhibit the catalysis of free radical reactions and thus to 
inhibit free-radical oxidation [28] (figure 4).
 
Figure 4. Diagramming of the main ways of action of doxorubicin and iron, which catalyzes  
the oxidative stress leading to cardiomyopathy and the application points of Mexicor 
Comment: Fe – iron, FAD/FADH2 – flavoprotein, GSH – reduced glutathione, GSSG – oxidized glutathione, H2O2 – hydrogen 
peroxide, NAD(PH)
+
 – nicotinamide adenine dinucleotide (phosphate), O2- – superoxide anion, OH – hydroxyl radical, SOD – 
superoxide dismutase. 
 Study of dose-dependent effect of 2-ethyl-6-methyl-3 hydroxypyridine succinate on the contractile function of 
isolated rat heat / O.G. Kesarev, L.M. Danilenko, M.V. Pokrovskii, A.S. Timokhina, A.V. Khovanskii // Research 
result: pharmacology and clinical pharmacology. – 2017. – Vol. 3, №1. – P. 3-9. 
8 
 
RESEARCH RESULT:  
PHARMACOLOGY AND CLINICAL PHARMACOLOGY 
The second application point of Mexicor in this 
model of pathology is glutathione. The concentration 
of disulfide forms of glutathione GSSG in the body is 
normally found in the tissue and blood of mammals is 
maintained at levels many times lower than for GSН. 
Oxidative stress can lead to a significant 
accumulation of GSSG in the liver and release it into 
the blood. The increase in the concentration of GSSG 
in the blood plasma, in turn, can cause oxidation of 
thiol groups of proteins basolateral membranes of 
tissue cells and its inactivation. The main 
mechanisms causing the depletion of the 
functionality of the glutathione system in doxorubicin 
model of pathology, are the inhibition of activity of 
glutathione reduce enzyme from the oxidized form 
(glucose-6-phosphate dehydrogenase), that leads to 
critical decline reduced glutathione, and then to the 
decrease in the activity of glutathione-dependent 
enzymes of antiradical protection, activation of free 
radical processes and death of cardiomyocytes [37-
41]. As directed pharmacological protection of 
cardiomyocytes there is pathogenetically explained 
the administration of drugs, whose action is directed 
at correcting the glutathione system. One of such 
directions can be the partial compensation of the 
antioxidant load attributable to the glutathione 
system. As such drug 3-hydroxypyridine derivatives, 
which is Mexicor can be used [31]. 
Conclusion 
Based on the results of study it can be concluded 
that the maximum increase of stability of the 
contractile apparatus of cardiac muscle was reached 
due to administration of the Mexicor at the dose of 
85.7 mg/kg/day, which convincingly demonstrate a 
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